CoChat

Validation of a 52-gene risk profile for outcome prediction in patients with idiopathic pulmonary fibrosis: an international, multicentre, cohort study

Open access

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

Abstract

Background The clinical course of idiopathic pulmonary fibrosis (IPF) is unpredictable. Clinical prediction tools are not accurate enough to predict disease outcomes.Methods We enrolled patients with IPF diagnosis in a six-cohort study at Yale University (New Haven, CT, USA), Imperial College London (London, UK), University of Chicago (Chicago, IL, USA), University of Pittsburgh (Pittsburgh, PA, USA), University of Freiburg (Freiburg im Breisgau, Germany), and Brigham and Women's Hospital-Harvard Medical School (Boston, MA, USA). Peripheral blood mononuclear cells or whole blood were collected at baseline from 425 participants and from 98 patients (23%) during 4-6 years' follow-up. A 52-gene signature was measured by the nCounter analysis system in four cohorts and extracted from microarray data (GeneChip) in the other two. We used the Scoring Algorithm for Molecular Subphenotypes (SAMS) to classify patients into low-risk or high-risk groups based on the 52-gene signature. We studied mortality with a competing risk model and transplant-free survival with a Cox proportional hazards model. We analysed timecourse data and response to antifibrotic drugs with linear mixed effect models.Findings The application of SAMS to the 52-gene signature identified two groups of patients with IPF (low-risk and high-risk), with significant differences in mortality or transplant-free survival in each of the six cohorts (hazard ratio [HR] range 2·03-4·37). Pooled data showed similar results for mortality (HR 2·18, 95% CI 1·53-3·09; p<0·0001) or transplant-free survival (2·04, 1·52-2·74; p<0·0001). Adding 52-gene risk profiles to the Gender, Age, and Physiology index significantly improved its mortality predictive accuracy. Temporal changes in SAMS scores were associated with changes in forced vital capacity (FVC) in two cohorts. Untreated patients did not shift their risk profile over time. A simultaneous increase in up score and decrease in down score was predictive of decreased transplant-free survival (3·18, 1·16-8·76; p=0·025) in the Pittsburgh cohort. A simultaneous decrease in up score and increase in down score after initiation of antifibrotic drugs was associated with a significant (p=0·0050) improvement in FVC in the Yale cohort.Interpretation The peripheral blood 52-gene expression signature is predictive of outcome in patients with IPF. The potential value of the 52-gene signature in predicting response to therapy should be determined in prospective studies.Funding The Pulmonary Fibrosis Foundation, the Harold Amos Medical Faculty Development Program of the Robert Wood Johnson Foundation, and the National Heart, Lung, and Blood Institute of the US National Institutes of Health.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2213-2600(17)30349-1

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Study design The outline summarizes the (a) time to event and (b) time course analysis design for this study including the cohorts, blood compartments, experiments and statistical methods used in each independent cohort and in the pooled data analysis. PBMC: Peripheral blood mononuclear cells. BWH-HMS: Brigham and Women’s Hospital-Harvard Medical School. Dates of enrollment for each cohort are included in figure 1a. For figure 1b, time is presented in years (average and range, in parenthesis).
Figure 1 Study design The outline summarizes the (a) time to event and (b) time course analysis design for this study including the cohorts, blood compartments, experiments and statistical methods used in each independent cohort and in the pooled data analysis. PBMC: Peripheral blood mononuclear cells. BWH-HMS: Brigham and Women’s Hospital-Harvard Medical School. Dates of enrollment for each cohort are included in figure 1a. For figure 1b, time is presented in years (average and range, in parenthesis).CC BY-NC-ND · PubMed Central
Figure 2 52-gene risk profiles are predictive of outcome in IPF (a) Clustering of IPF patients based on52-gene risk profiles (high vs low) derived using SAMS in each one of the six cohorts studied. Every row represents a gene and every column a patient. Color scale is shown adjacent to heat maps in log-based two scale; yellow denotes increase over the geometric mean of samples and purple, decrease. (b) Mortality and Transplant-free survival (TFS) differs between high vs low risk profiles based on the 52-gene signature in each independent cohort.
Figure 2 52-gene risk profiles are predictive of outcome in IPF (a) Clustering of IPF patients based on52-gene risk profiles (high vs low) derived using SAMS in each one of the six cohorts studied. Every row represents a gene and every column a patient. Color scale is shown adjacent to heat maps in log-based two scale; yellow denotes increase over the geometric mean of samples and purple, decrease. (b) Mortality and Transplant-free survival (TFS) differs between high vs low risk profiles based on the 52-gene signature in each independent cohort.CC BY-NC-ND · PubMed Central
Figure 3 52-gene risk profiles are predictive of outcome independent of demographic and clinical variables (a) Pooled data analysis comparing high vs low risk profile patients from all cohorts. Color scale is shown adjacent to heat maps in log-based two scale. (b) Mortality and (c) Transplant-free survival (TFS) differs between high vs low risk patients from all cohorts after adjusting for age, gender, FVC% and immunosuppressive therapy. (d) Area Under the Curve (AUC) of time-dependent ROC analysis for (d) mortality and (e)TFS based on the GAP index alone or the G-GAP index in all patients.
Figure 3 52-gene risk profiles are predictive of outcome independent of demographic and clinical variables (a) Pooled data analysis comparing high vs low risk profile patients from all cohorts. Color scale is shown adjacent to heat maps in log-based two scale. (b) Mortality and (c) Transplant-free survival (TFS) differs between high vs low risk patients from all cohorts after adjusting for age, gender, FVC% and immunosuppressive therapy. (d) Area Under the Curve (AUC) of time-dependent ROC analysis for (d) mortality and (e)TFS based on the GAP index alone or the G-GAP index in all patients.CC BY-NC-ND · PubMed Central
Figure 4 52-gene signature trends over time demonstrate association with disease progression and survival (a) up and down (b) scores from SAMS, and (c) FVC volumes do not shift their trends over time in high (continuous red line) vs low (continuous black line) risk groups (Pittsburgh cohort). Pointwise confidence intervals are represented in purple. (d) Bidirectional changes in SAMS scores (Simultaneous increase in up score and decrease in down score) can be observed during disease course in IPF and are more prominent in high risk individuals (example shown in dotted black line box). (e) Bidirectional changes in SAMS scores are predictive of Transplant-free survival (TFS). Dotted blue line (high risk) –Pittsburgh cohort patients with 30-day bidirectional changes in SAMS scores ≥10%. Continuous red line (low risk) – Pittsburgh cohort patients with 30-day bidirectional changes in SAMS scores <10%. Results adjusted by age, gender, FVC and immunosuppressive therapy.
Figure 4 52-gene signature trends over time demonstrate association with disease progression and survival (a) up and down (b) scores from SAMS, and (c) FVC volumes do not shift their trends over time in high (continuous red line) vs low (continuous black line) risk groups (Pittsburgh cohort). Pointwise confidence intervals are represented in purple. (d) Bidirectional changes in SAMS scores (Simultaneous increase in up score and decrease in down score) can be observed during disease course in IPF and are more prominent in high risk individuals (example shown in dotted black line box). (e) Bidirectional changes in SAMS scores are predictive of Transplant-free survival (TFS). Dotted blue line (high risk) –Pittsburgh cohort patients with 30-day bidirectional changes in SAMS scores ≥10%. Continuous red line (low risk) – Pittsburgh cohort patients with 30-day bidirectional changes in SAMS scores <10%. Results adjusted by age, gender, FVC and immunosuppressive therapy.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 46 references

Cited by

See all 182

Metadata

Authors
Herazo-Maya, J. D., Sun, J., Molyneaux, P. L., Li, Q., Villalba, J. A., Tzouvelekis, A., Lynn, H., Juan-Guardela, B. M., Risquez, C., Osorio, J. C., Yan, X., Michel, G., Aurelien, N., Lindell, K. O., Klesen, M. J., Moffatt, M. F., Cookson, W. O., Zhang, Y., Garcia, J. G. N., Noth, I., Prasse, A., Bar-Joseph, Z., Gibson, K. F., Zhao, H., Herzog, E. L., Rosas, I. O., Maher, T. M., & Kaminski, N.
Affiliations
  • Yale University (US)
  • Imperial College London (GB)
  • Brigham and Women's Hospital (US)
  • Mayo Clinic (US)
  • University of Pittsburgh (US)
  • University of Arizona (US)
  • University of Chicago (US)
  • University of Freiburg (DE)
  • National Institute for Health and Care Research (GB)
Corresponding author
Kaminski, Naftali
Venue
The Lancet Respiratory Medicine
Publisher
Elsevier BV
Published
2017-11
Volume
5
Issue
11
Pages
857-868
ISSN
2213-2600 (ISSN-L)
OpenAlex
W2756020545
Cited by
175
References
46
Citations by year
2026: 13 · 2025: 20 · 2024: 31 · 2023: 29 · 2022: 17 · 2021: 17 · 2020: 12 · 2019: 14 · 2018: 21 · 2017: 1
FWCI
10.86
Type
journal article
Language
en
Open access
Licence
  • cc-by-nc-nd
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet Respiratory Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion, cc-by-nc-nd)
  • PubMed Central (acceptedVersion, cc-by-nc-nd)
  • Spiral (Imperial College London) (submittedVersion, cc-by-nc-nd)
Funders
  • U.S. Department of Veterans Affairs (CDA13-017)
  • Wellcome Trust
  • National Institute for Health and Care Research (CS-2013-13-017)
  • National Institutes of Health (5r01hl125850-04)
  • National Heart, Lung, and Blood Institute (U01HL112707, U01HL108642, R01-HL-125850, T32HL007778, R01HL109233, UH3HL123886, UH2HL123886, R01HL127349)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
  • Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
Keywords
idiopathic pulmonary fibrosis, mortality prediction, transplant-free survival, antifibrotic agents, forced vital capacity, peripheral blood mononuclear cells, gene expression profiling, competing risk model, prognostic factors, risk stratification, lung transplantation
MeSH terms
Aged, Female, Genetic Markers, Genetic Testing, Humans, Leukocytes, Mononuclear, Male, Middle Aged, Prognosis, Risk Factors, Time Factors, Vital Capacity, Cohort Studies, Linear Models, Proportional Hazards Models, Risk Assessment, Oligonucleotide Array Sequence Analysis, Gene Expression Profiling, Idiopathic Pulmonary Fibrosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Validation of a 52-gene risk profile for outcome prediction in patients with idiopathic pulmonary fibrosis: an international, multicentre, cohort study. https://app.cochat.ai/papers/10.1016/s2213-2600(17)30349-1
The paper
Herazo-Maya, J. D., Sun, J., Molyneaux, P. L., Li, Q., Villalba, J. A., Tzouvelekis, A., Lynn, H., Juan-Guardela, B. M., Risquez, C., Osorio, J. C., Yan, X., Michel, G., Aurelien, N., Lindell, K. O., Klesen, M. J., Moffatt, M. F., Cookson, W. O., Zhang, Y., Garcia, J. G. N., . . . Kaminski, N. (2017). Validation of a 52-gene risk profile for outcome prediction in patients with idiopathic pulmonary fibrosis: an international, multicentre, cohort study. The Lancet Respiratory Medicine. https://doi.org/10.1016/s2213-2600(17)30349-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.